Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents. The company was founded in 2007 and is headquartered in Tianjin, China.
Sino Medical Sciences Technology In (688108) - Total Assets
Latest total assets as of September 2025: CN¥1.34 Billion CNY
Based on the latest financial reports, Sino Medical Sciences Technology In (688108) holds total assets worth CN¥1.34 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sino Medical Sciences Technology In - Total Assets Trend (2016–2024)
This chart illustrates how Sino Medical Sciences Technology In’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sino Medical Sciences Technology In - Asset Composition Analysis
Current Asset Composition (December 2024)
Sino Medical Sciences Technology In's total assets of CN¥1.34 Billion consist of 31.0% current assets and 69.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 22.4% |
| Accounts Receivable | CN¥18.90 Million | 1.5% |
| Inventory | CN¥89.51 Million | 6.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥582.39 Million | 44.8% |
| Goodwill | CN¥46.22 Million | 3.6% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sino Medical Sciences Technology In's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sino Medical Sciences Technology In's current assets represent 31.0% of total assets in 2024, a decrease from 53.7% in 2016.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2024, up from 15.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 26.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 44.8% of total assets.
Sino Medical Sciences Technology In Competitors by Total Assets
Key competitors of Sino Medical Sciences Technology In based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Sino Medical Sciences Technology In - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sino Medical Sciences Technology In generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sino Medical Sciences Technology In generates $ 0.12 in net profit.
Sino Medical Sciences Technology In - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.17 | 2.38 | 7.85 |
| Quick Ratio | 1.71 | 1.61 | 7.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥261.36 Million | CN¥ 215.89 Million | CN¥ 631.26 Million |
Sino Medical Sciences Technology In - Advanced Valuation Insights
This section examines the relationship between Sino Medical Sciences Technology In's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.33 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | CN¥1.30 Billion |
| Market Capitalization | $854.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sino Medical Sciences Technology In's assets below their book value (0.66 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sino Medical Sciences Technology In's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sino Medical Sciences Technology In (2016–2024)
The table below shows the annual total assets of Sino Medical Sciences Technology In from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.30 Billion | +9.68% |
| 2023-12-31 | CN¥1.19 Billion | +11.07% |
| 2022-12-31 | CN¥1.07 Billion | -3.22% |
| 2021-12-31 | CN¥1.10 Billion | -9.40% |
| 2020-12-31 | CN¥1.22 Billion | +0.99% |
| 2019-12-31 | CN¥1.21 Billion | +49.56% |
| 2018-12-31 | CN¥806.10 Million | +13.48% |
| 2017-12-31 | CN¥710.33 Million | +152.95% |
| 2016-12-31 | CN¥280.81 Million | -- |